KTTA

Pasithea Therapeutics Corp. (KTTA) | Rumor.io

Pasithea Therapeutics

KTTA

Attention (50-day avg)0%

Attention rank (50-day avg)#3,930

Bullish sentiment (50-day avg)100%

Price to earnings ratio-0.16

Market capitalization16M

Earnings per share-1.35

Dividend yield (TTM)—

Revenue (annual)0

Net income (annual)-20.4M

Social

What share of all stock conversation is about KTTA?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% 0	0% 0	0% 0

Jul 13

The stock price of Pasithea Therapeutics Corp. (KTTA) is experiencing a significant decline, with a change of -1.5199999999999991.
Many community members are uncertain about whether to hold onto their shares or cut losses, with some considering it a buying opportunity while others are leaning towards selling.
The decline has sparked worries about the company's future, with some speculating about technical or news reasons to hold or sell, and others considering whether to average down or preserve capital.

Generated by AI

Sentiment

Of the messages about KTTA that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	—	83.4% +2.81
Bearish	—	—	—	16.6% -2.81

Bullish· Dec 2

The company has $60M in cash, making it difficult to short the stock and setting the stage for a potential squeeze.
Insiders are buying shares, indicating confidence in the company's prospects.
The stock's chart is showing bullish patterns, suggesting a potential rise to $1.5 and a 40% profit for early investors.

Bearish· Dec 1

The author believes Pasithea Therapeutics Corp. (KTTA) is a "bear's trap" and will continue to fall, with a 93% chance of dropping below $1 and getting delisted.
The company's recent dilution of $60 million will lead to a significant drop in stock value, with the author predicting it will fall to under $1.
The author suggests that Pasithea Therapeutics Corp. (KTTA) is a "ponzi scam" and that its management made a choice between raising $60 million or allowing the stock price to increase, ultimately deciding to "trash" the stock value.

Generated by AI

Topics

Of the messages about KTTA that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	100%	100%	12.49%
Analysts	—	0%	0%	26.2%
Controversies	—	0%	0%	0.47%
Earnings	—	0%	0%	0%
Macro	—	0%	0%	25.92%
Technical Analysis	—	0%	0%	34.93%

Announcements· Nov 24

Pasithea Therapeutics Corp. ($KTTA) announces positive PAS-004 tablet pharmacokinetic (PK) data in an ongoing Phase 1/1b trial in adult NF1 patients.
The company completes Cohort 7 in an ongoing Phase 1 trial of PAS-004 in advanced cancer patients, with positive safety, pharmacokinetic (PK), and pharmacodynamic (PD) data.
Pasithea Therapeutics Corp. ($KTTA) announces completion of Cohort 7 in an ongoing Phase 1 trial of PAS-004, with positive safety, PK, and PD data, and receives approval to escalate to Cohort 8.

Technical Analysis· Apr 10

The author believes $KTTA will break 1.60 and expects a significant price increase, potentially reaching 1.80 or more.
The MACD and RSI indicators are still bullish, suggesting that the asset may experience at least one more bull run.
The author identifies 1.40 as significant support and believes that once 1.60 is broken, the asset will experience a strong price increase.

Generated by AI

Community

Of the messages about KTTA, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	100%	100%	34.33%
Newcomers	—	0%	0%	65.67%

Regulars· Nov 24

Pasithea Therapeutics Corp. announces positive PK data in Phase 1/1b trial for PAS-004 in adult NF1 patients, with no safety concerns.
The company completes Cohort 7 in Phase 1 trial of PAS-004 in advanced cancer patients, showing positive safety, PK, and PD data.
$KTTA stock price rises 64% in a short period, breaking VWAP, and is expected to continue on an uptrend with increased volume.

Newcomers· Dec 1

The newcomers are focused on the volatility of KTTA, with one post noting it's one of the most volatile stocks, and another post watching for higher lows to hold and a push through intraday resistance for confirmation.
The company's lead program, an oral next-generation MEK inhibitor, is being discussed, which has received FDA orphan drug designation and was initially developed for the treatment of neurofibromatosis type 1 (NF1).
The price movement of KTTA is being watched, with a post noting it closed at 1.25 after a strong 38 percent move with volume, and another post predicting it could push toward 1.55 if it holds support around 1.10 to 1.15.

Generated by AI

- Pasithea has been selected to present cutaneous neurofibromas (CN) clinical data in an oral presentation - Pasithea has been selected to present plexiform neurofibromas (PN) clinical data in a poster presentation - The European Neurofibromatosis Conference 2026 will take place in Vienna, Austria, from November 12–14, 2026 MIAMI, Sept. 14, 2026 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (Nasdaq: KTTA) (“Pasithea” or the “Company”), a clinical-stage biotechnology company developing PAS-004,

16d agoYahoo Finance

Pasithea Therapeutics Announces Participation in Two September 2026 Investor Conferences

-- Company will hold one-on-one investor meetings at the 12th Annual Cantor Global Healthcare Conference (September 9-11) and will present at the H.C. Wainwright 28th Annual Global Investment Conference (September 14-16) -- MIAMI, Sept. 03, 2026 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (NASDAQ: KTTA) ("Pasithea" or the "Company"), a clinical-stage biotechnology company developing PAS-004, a next-generation macrocyclic oral MEK inhibitor, for the long-term treatment of chronic diseases inc

26d agoYahoo! Finance Canada

Pasithea Therapeutics Receives Nasdaq Extension on Listing Compliance

Detailed price information for Pasithea Therapeutics Corp (KTTA-Q) from The Globe and Mail including charting and trades.

1mo agoThe Globe and Mail

Pasithea Therapeutics Announces Presentation of PAS-004 Data to European Society for Medical Oncology (ESMO) Congress 2026

-- Phase I Dose-Escalation Study of the Safety and Pharmacokinetics of PAS-004, a Macrocyclic MEK Inhibitor, for the Treatment of Patients with MAPK Pathway Driven Advanced Solid Tumors will be presented Friday, October 23, 2026 -- Full abstract will be published on ESMO website per Congress’ standard embargo schedule MIAMI, July 21, 2026 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (NASDAQ: KTTA) ("Pasithea" or the "Company"), a clinical-stage biotechnology company developing PAS-004, a next

2mo agoYahoo Finance

Pasithea Therapeutics Announces Participation in B. Riley Securities Mind, Muscle & Vision Summit

July 16 in Boston, management will engage with investors and industry participants at the healthcare-focused event covering neuropsychiatry, neurodegeneration, neuromuscular disease, ophthalmology, and neuroimmunologyMIAMI, July 08, 2026 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (NASDAQ: KTTA) (“Pasithea” or the “Company”), a clinical-stage biotechnology company developing PAS-004, a next-generation macrocyclic MEK inhibitor for the long-term treatment of chronic diseases including the neu

2mo agoYahoo Finance

Also Discussed

Investors talking about KTTA also mention

#	Name	Attention
1	Longeveron Inc. Class A Common StockLGVN	0%0
2	Biofrontera Inc.BFRI	0%0
3	iSpecimen Inc.ISPC	0%0
4	PTPI - Petros Pharmaceuticals, Inc.	——
5	Society Pass IncorporatedSOPA	0%0
6	Cumberland Pharmaceuticals Inc.CPIX	0%new
7	Context Therapeutics Inc.CNTX	0%0
8	Ensysce Biosciences, Inc. Common StockENSC	0%0
9	Immix Biopharma, Inc.IMMX	0.03%+0.03
10	LSDI - Lucy Scientific Discovery Inc.	——

Pasithea Therapeutics Corp.

Healthcare
Biotechnology

Pasithea Therapeutics Corp. is a biotechnology company focused on the discovery, research, and development of innovative treatments for central nervous system disorders and RASopathies. The company’s current programs center on PAS-004, a next-generation macrocyclic MEK inhibitor being developed for indications that include neurofibromatosis type 1-associated plexiform neurofibromas and selected oncology uses. Pasithea Therapeutics Corp. also works on additional therapeutic candidates aimed at neurological and psychiatric conditions, reflecting a broader emphasis on diseases with significant unmet medical need. The company operates through therapeutic development activities and clinic-related services, positioning itself across both drug research and patient-facing healthcare applications. Based in Miami Beach, Florida, Pasithea Therapeutics Corp. plays a role in the clinical-stage biotechnology market by advancing targeted treatment candidates for complex disorders.

Website

Location

1111 Lincoln Road

Miami Beach, FL, 33139

United States

Social

What share of all stock conversation is about KTTA?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% 0	0% 0	0% 0

Jul 13

The stock price of Pasithea Therapeutics Corp. (KTTA) is experiencing a significant decline, with a change of -1.5199999999999991.
Many community members are uncertain about whether to hold onto their shares or cut losses, with some considering it a buying opportunity while others are leaning towards selling.
The decline has sparked worries about the company's future, with some speculating about technical or news reasons to hold or sell, and others considering whether to average down or preserve capital.

Generated by AI

Sentiment

Of the messages about KTTA that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	—	83.4% +2.81
Bearish	—	—	—	16.6% -2.81

Bullish· Dec 2

The company has $60M in cash, making it difficult to short the stock and setting the stage for a potential squeeze.
Insiders are buying shares, indicating confidence in the company's prospects.
The stock's chart is showing bullish patterns, suggesting a potential rise to $1.5 and a 40% profit for early investors.

Bearish· Dec 1

The author believes Pasithea Therapeutics Corp. (KTTA) is a "bear's trap" and will continue to fall, with a 93% chance of dropping below $1 and getting delisted.
The company's recent dilution of $60 million will lead to a significant drop in stock value, with the author predicting it will fall to under $1.
The author suggests that Pasithea Therapeutics Corp. (KTTA) is a "ponzi scam" and that its management made a choice between raising $60 million or allowing the stock price to increase, ultimately deciding to "trash" the stock value.

Generated by AI

Topics

Of the messages about KTTA that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	100%	100%	12.49%
Analysts	—	0%	0%	26.2%
Controversies	—	0%	0%	0.47%
Earnings	—	0%	0%	0%
Macro	—	0%	0%	25.92%
Technical Analysis	—	0%	0%	34.93%

Announcements· Nov 24

Pasithea Therapeutics Corp. ($KTTA) announces positive PAS-004 tablet pharmacokinetic (PK) data in an ongoing Phase 1/1b trial in adult NF1 patients.
The company completes Cohort 7 in an ongoing Phase 1 trial of PAS-004 in advanced cancer patients, with positive safety, pharmacokinetic (PK), and pharmacodynamic (PD) data.
Pasithea Therapeutics Corp. ($KTTA) announces completion of Cohort 7 in an ongoing Phase 1 trial of PAS-004, with positive safety, PK, and PD data, and receives approval to escalate to Cohort 8.

Technical Analysis· Apr 10

The author believes $KTTA will break 1.60 and expects a significant price increase, potentially reaching 1.80 or more.
The MACD and RSI indicators are still bullish, suggesting that the asset may experience at least one more bull run.
The author identifies 1.40 as significant support and believes that once 1.60 is broken, the asset will experience a strong price increase.

Generated by AI

Community

Of the messages about KTTA, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	100%	100%	34.33%
Newcomers	—	0%	0%	65.67%

Regulars· Nov 24

Pasithea Therapeutics Corp. announces positive PK data in Phase 1/1b trial for PAS-004 in adult NF1 patients, with no safety concerns.
The company completes Cohort 7 in Phase 1 trial of PAS-004 in advanced cancer patients, showing positive safety, PK, and PD data.
$KTTA stock price rises 64% in a short period, breaking VWAP, and is expected to continue on an uptrend with increased volume.

Newcomers· Dec 1

The newcomers are focused on the volatility of KTTA, with one post noting it's one of the most volatile stocks, and another post watching for higher lows to hold and a push through intraday resistance for confirmation.
The company's lead program, an oral next-generation MEK inhibitor, is being discussed, which has received FDA orphan drug designation and was initially developed for the treatment of neurofibromatosis type 1 (NF1).
The price movement of KTTA is being watched, with a post noting it closed at 1.25 after a strong 38 percent move with volume, and another post predicting it could push toward 1.55 if it holds support around 1.10 to 1.15.

Generated by AI

Pasithea Therapeutics

Social

Jul 13

Sentiment

Bullish· Dec 2

Bearish· Dec 1

Topics

Announcements· Nov 24

Technical Analysis· Apr 10

Community

Regulars· Nov 24

Newcomers· Dec 1

News

Pasithea Therapeutics Announces Presentation of Initial PAS-004 Clinical Data from Ongoing Phase 1/1b Clinical Trial in Adult NF1 Patients at the 2026 European Neurofibromatosis Conference

Pasithea Therapeutics Announces Participation in Two September 2026 Investor Conferences

Pasithea Therapeutics Receives Nasdaq Extension on Listing Compliance

Pasithea Therapeutics Announces Presentation of PAS-004 Data to European Society for Medical Oncology (ESMO) Congress 2026

Pasithea Therapeutics Announces Participation in B. Riley Securities Mind, Muscle & Vision Summit

Also Discussed

Pasithea Therapeutics Corp.

Company Information

Location

News

Pasithea Therapeutics Announces Presentation of Initial PAS-004 Clinical Data from Ongoing Phase 1/1b Clinical Trial in Adult NF1 Patients at the 2026 European Neurofibromatosis Conference

Pasithea Therapeutics Announces Participation in Two September 2026 Investor Conferences

Pasithea Therapeutics Receives Nasdaq Extension on Listing Compliance

Pasithea Therapeutics Announces Presentation of PAS-004 Data to European Society for Medical Oncology (ESMO) Congress 2026

Pasithea Therapeutics Announces Participation in B. Riley Securities Mind, Muscle & Vision Summit

Also Discussed

Social

Jul 13

Sentiment

Bullish· Dec 2

Bearish· Dec 1

Topics

Announcements· Nov 24

Technical Analysis· Apr 10

Community

Regulars· Nov 24

Newcomers· Dec 1